ArticleOncology letters2026
Diffuse peritoneal mesothelioma presenting with the appearance of mesenteric panniculitis: A case report.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse peritoneal mesothelioma (DPM) is a rare and aggressive malignancy of the peritoneum. Early symptoms are non-specific and the condition is liable to misdiagnosis. In the present case, a 54-year-old man was misdiagnosed between April 2020 and October 2021 with mesenteric panniculitis. The patient later presented with a 2-month history of persistent upper-middle abdominal pain and weight loss in April 2022. A laparoscopic biopsy was performed and the sample was positive for Wilms tumor protein, Hector Battifora mesothelial-1 and podoplanin. Therefore, a diagnosis of DPM was made. A total of six cycles of pemetrexed-cisplatin chemotherapy were given and elicited a partial response. The disease progressed and intraperitoneal bevacizumab-cisplatin therapy was administered, which was ineffective. The patient died 13 months post-diagnosis. DPM often has a similar presentation to benign conditions, such as mesenteric panniculitis. Correct diagnosis is facilitated by an awareness of occupational exposure risk, such as that of asphalt exposure for the present case, and early histopathological evaluation. The prognosis for DPM remains poor despite multimodal therapy, and novel therapeutic strategies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.